IL2 and neoplasm: We further found that the treatment of vvDD-IL-2-RG or vvDD-IL-2-RG plus anti-PD-1/PD-L1 antibody for intraperitoneal tumour could elicit an abscopal effect on non-treated subcutaneous tumours in the flank (Fig. 4g–i and Supplementary Fig. 13a–c).